Analysts Set Atossa Genetics Inc. (NASDAQ:ATOS) PT at $95.00

Atossa Genetics Inc. (NASDAQ:ATOS) has been given a consensus rating of “Hold” by the five brokerages that are currently covering the stock, MarketBeat reports. Two equities research analysts have rated the stock with a sell rating, two have assigned a buy rating and one has given a strong buy rating to the company. The average 1 year price target among brokers that have issued ratings on the stock in the last year is $95.00.

Several analysts have recently weighed in on ATOS shares. Ascendiant Capital Markets raised their price objective on shares of Atossa Genetics from $116.25 to $120.00 and gave the company a “buy” rating in a research report on Monday, December 8th. Weiss Ratings restated a “sell (d-)” rating on shares of Atossa Genetics in a research report on Wednesday, January 21st.

Atossa Genetics Trading Down 0.8%

Shares of ATOS opened at $4.97 on Friday. The stock has a 50-day moving average price of $6.48 and a 200-day moving average price of $10.31. The company has a market cap of $42.79 million, a PE ratio of -1.38 and a beta of 1.42. Atossa Genetics has a 12-month low of $3.76 and a 12-month high of $19.35.

Institutional Trading of Atossa Genetics

Hedge funds have recently bought and sold shares of the company. &PARTNERS bought a new position in Atossa Genetics during the fourth quarter valued at approximately $25,000. Hudson Bay Capital Management LP bought a new stake in shares of Atossa Genetics in the 2nd quarter worth approximately $26,000. Gallagher Capital Advisors LLC purchased a new stake in shares of Atossa Genetics in the 3rd quarter valued at $27,000. JPMorgan Chase & Co. boosted its stake in shares of Atossa Genetics by 1,294.2% in the 3rd quarter. JPMorgan Chase & Co. now owns 38,215 shares of the company’s stock valued at $33,000 after purchasing an additional 35,474 shares in the last quarter. Finally, Catalyst Funds Management Pty Ltd bought a new position in shares of Atossa Genetics during the 2nd quarter valued at $49,000. Institutional investors own 12.74% of the company’s stock.

About Atossa Genetics

Atossa Genetics, Inc is a clinical-stage biotechnology company based in Seattle, Washington, focused on developing therapeutics and diagnostic products for breast cancer and other breast-related conditions. The company’s mission centers on delivering targeted, minimally invasive solutions that address early detection, treatment, and prevention in women at risk for or diagnosed with breast malignancies.

The company’s pipeline includes Z-Endoxifen, an oral formulation of endoxifen designed to treat and prevent estrogen receptor–positive breast cancers, particularly in patients with ductal carcinoma in situ or those at high risk of recurrence.